Biotech M&A – 2022 Deals

Biotech M&A – 2022 Deals

Biotech M&A With a Slow Start in 2022: More Deals to Follow?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareNotesLink to the news PR
01/19/2022UCB, Brussels, BelgiumUCBZogenix ZGNX$1.9B$26.00$2 CVR, Epilepsy drughttps://prn.to/3nGq1WJ
02/14/2022Collegium PharmaceuticalCOLLBioDelivery Sciences BDSI$604M$5.60Pain Portfoliohttps://bit.ly/3rOyVnK
04/07/2022PfizerPFEReViralPrivate$525M-Antiviral targeting RSV- respiratory syncytial virushttps://bwnews.pr/3ujk7i5
04/13/2022GlaxoSmithKlineGSKSierra OncologySRRA$1.9B$55.00Momelotinib potential of myelofibrosis patients with anaemia https://bwnews.pr/3jx9wtF
04/13/2022HalozymeHALOAntares PharmaATRS$960M$5.60auto injector platformhttps://prn.to/3jA7xoo
04/19/2022RegeneronRGENCheckmate PharmaceuticalsCMPI$250M$10.50 vidutolimod, CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonisthttps://bit.ly/3Oxvhbc
05/10/2022PfizerPFEBiohaven PharmaceuticalBHVN $11.6B$148.50Plus 0.5 of a share of a new publicly traded company that retains Biohaven’s non-CGRP pipeline compoundshttps://bwnews.pr/3tV7KbA
06/03/2022Bristol Myers SquibbBMYTurning Point TherapeuticsTPTX$4.1B$76.00ROS1/NTRK Inhibitor for ROS1-positive First-Line NSCLChttps://bit.ly/3yg1C06
06/23/2022invoX Pharma - UKINVOXF-star TherapeuticsFSTX$161M$7.12bispecific antibody platformhttps://bit.ly/3OSteOn
06/23/2022Gurnet Point CapitalPrivateRadius HealthRDUS$890M$10.00CVR $1.00https://bit.ly/3zXw9Rr
06/27/2022IpsenIPSEYEpizymeEPZM$247M$1.45CVR $1.00 achievement of $250M net sales of Tazverikhttps://bwnews.pr/3usvaFx
07/11/2022InnovivaINVALa Jolla PharmaceuticalLJPC$149M$5.95and an incremental $0.28/shr for the divestiture of a non-core assethttps://bwnews.pr/3IqJyDT
07/11/2022VertexVRTXViaCytePrivate$320M-Stem-Cell VX-880 Programs in Type 1 Diabeteshttps://bwnews.pr/3nR0tWE
07/25/2022Ginkgo BioworksDNAZymergenZY$300M~$2.680.9179 Ginkgo shares for each Zymergen share (~$2.92) https://prn.to/3otX3cM
08/04/2022AmgenAMGNChemoCentryx, IncCCXI$3.7B$52TAVNEOS® for Patients With Serious Autoimmune Diseasehttps://prn.to/3OX4bcw
08/04/2022GileadGILDMiroBioPrivate$405M-Pipeline of Immune Checkpoint Agonistshttps://bwnews.pr/3BBW3ep
08/08/2022PfizerPFEGlobal Blood Therapeutics GBT$5.4B$68.50sickle cell disease (SCD)https://bit.ly/3bHcnQA

For M&A 2021 full table click here https://www.chimeraresearchgroup.com/biotech-ma-2021-deals/

Recent Press

Slider

Log In

JoinLost Password?